Trial Profile
A retrospective trial comparing efficacy of treatment with Ruxolitinib and allogeneic hematopoietic cell transplantation in german patients with myelofibrosis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Feb 2016
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Allotransplant rejection; Myelofibrosis
- Focus Therapeutic Use
- 05 Feb 2016 New trial record
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology